ECSP22078679A - Compuestos de bencimidazol para el tratamiento de trastornos metabólicos - Google Patents

Compuestos de bencimidazol para el tratamiento de trastornos metabólicos

Info

Publication number
ECSP22078679A
ECSP22078679A ECSENADI202278679A ECDI202278679A ECSP22078679A EC SP22078679 A ECSP22078679 A EC SP22078679A EC SENADI202278679 A ECSENADI202278679 A EC SENADI202278679A EC DI202278679 A ECDI202278679 A EC DI202278679A EC SP22078679 A ECSP22078679 A EC SP22078679A
Authority
EC
Ecuador
Prior art keywords
treatment
bencimidazole
compounds
metabolic disorders
formula
Prior art date
Application number
ECSENADI202278679A
Other languages
English (en)
Inventor
Azevedo Hatylas Felype Zaneti De
Natanael Dante Segretti
Alessandra Mascarello
Cristiano Ruch Werneck Guimarães
Junior Marcos Antonio Ferreira
Original Assignee
Ache Laboratorios Farmaceuticos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos Sa filed Critical Ache Laboratorios Farmaceuticos Sa
Publication of ECSP22078679A publication Critical patent/ECSP22078679A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona en forma amplia con un compuesto de bencimidazol de la Fórmula I para el tratamiento de obesidad, diabetes, enfermedad de hígado graso no alcohólico y esteatohepatitis no alcohólica: Fórmula I o sales, cristales, hidratos, prodrogas, metabolitos o solvatos del mismo farmacéuticamente aceptables.
ECSENADI202278679A 2020-04-15 2022-10-11 Compuestos de bencimidazol para el tratamiento de trastornos metabólicos ECSP22078679A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063010128P 2020-04-15 2020-04-15

Publications (1)

Publication Number Publication Date
ECSP22078679A true ECSP22078679A (es) 2022-11-30

Family

ID=78083461

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202278679A ECSP22078679A (es) 2020-04-15 2022-10-11 Compuestos de bencimidazol para el tratamiento de trastornos metabólicos

Country Status (15)

Country Link
US (1) US20230128304A1 (es)
EP (1) EP4136079A4 (es)
JP (1) JP2023522062A (es)
KR (1) KR20230002427A (es)
CN (1) CN115335363A (es)
AR (1) AR121842A1 (es)
AU (1) AU2021256476A1 (es)
CA (1) CA3171746A1 (es)
CL (1) CL2022002821A1 (es)
CO (1) CO2022012616A2 (es)
EC (1) ECSP22078679A (es)
GB (1) GB2609793B (es)
MX (1) MX2022009872A (es)
PE (1) PE20221568A1 (es)
WO (1) WO2021207816A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
AU2003902860A0 (en) * 2003-06-06 2003-06-26 Daicel Chemical Industries, Ltd Benzimidazole compounds
ES2331274B1 (es) * 2007-10-25 2010-10-21 Ferrer Internacional, S.A. Compuesto de indolina.
MX2011003239A (es) * 2008-09-26 2011-04-28 Merck Sharp & Dohme Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos.
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
ES2711808B2 (es) * 2017-11-02 2020-03-13 Univ Granada Uso de un agonista de melatonina para inducir la para inducir adipocitos beige en el tejido adiposo blanco

Also Published As

Publication number Publication date
MX2022009872A (es) 2022-08-22
GB202215434D0 (en) 2022-11-30
AU2021256476A1 (en) 2022-08-25
AR121842A1 (es) 2022-07-13
CN115335363A (zh) 2022-11-11
WO2021207816A1 (en) 2021-10-21
CA3171746A1 (en) 2021-10-21
GB2609793A (en) 2023-02-15
CL2022002821A1 (es) 2023-04-10
EP4136079A4 (en) 2024-05-15
JP2023522062A (ja) 2023-05-26
PE20221568A1 (es) 2022-10-06
US20230128304A1 (en) 2023-04-27
GB2609793A8 (en) 2023-03-22
CO2022012616A2 (es) 2022-10-21
GB2609793B (en) 2024-05-08
KR20230002427A (ko) 2023-01-05
EP4136079A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
UY32622A (es) Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
CO2021009240A2 (es) Compuestos moduladores de fxr (nr1h4)
CR11470A (es) Compuestos organicos
CO6680645A2 (es) Inhibidores de oxadiazol de la producción de leucotrieno
NZ721645A (en) Compounds for use as gpr120 agonists
HN2009003002A (es) Compuestos de piridopirimidinonas inhibidores de pi3k-alfa
AR069165A1 (es) Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
CO6321227A2 (es) Moduladores del receptor de la prostaciclina ( pg12) utiles para el tratamiento de transtornos relacionados con este
HN2009003214A (es) Compuestos de pirazina sustituidos
NZ587518A (en) Crystalline form III of (3,5-bis trifluoromethyl)-N-[4-methyl-3-({ 4-(pyridin-3 yl)-pyrimidin-2-yl} amino)-phenyl]-benzamide
CO2021000932A2 (es) Forma cristalina de compuesto profármaco de lanosterol y aplicación de la misma
UY32877A (es) Inhibidores heteroarílicos de cinasa.
WO2014059232A3 (en) Substituted spiropiperidinyl compounds useful as gpr120 agonists
MX344663B (es) Medicamento dirigido a tumor derivado de combretastatina a4.
PE20191103A1 (es) Inhibidores de dopamina-b-hidroxilasa
AR087803A1 (es) N-hidroxi-4-{2-[3-n,n-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida y esquema para administrarla
CL2023001225A1 (es) Forma de cristal iv de compuesto agonista del receptor de melanocortina, y metodo de preparacion
CO2023006515A2 (es) Forma cristalina i del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CO2023006513A2 (es) Forma cristalina iii del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CO2023006517A2 (es) Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CL2022002821A1 (es) Compuestos de bencimidazol para el tratamiento de trastornos metabólicos
MX2020004667A (es) Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas.